Literature DB >> 6245359

Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia.

K G Blume, E Beutler, K J Bross, R K Chillar, O B Ellington, J L Fahey, M J Farbstein, S J Forman, G M Schmidt, E P Scott, W E Spruce, M A Turner, J L Wolf.   

Abstract

Thirty-three patients with acute leukemia (15 with lymphoblastic leukemia and 18 with myeloblastic leukemia) were entered into a program of high-dose radiochemotherapy followed by allogeneic bone-marrow transplantation. These patients were in various clinical stages of disease. Of 10 in complete hematologic remission at the time of transplantation, seven were alive without maintenance therapy at the time of evaluation, eight to 35 months after grafting; one was in relapse. Of 11 who received transplants during partial remission, six were in remission without further treatment eight to 33 months after transplantation. In 12 the disease was refractory to chemotherapy when preparation for transplantation was started, and only one of them was alive and free of disease after 10 months. Recurrent leukemia, graft-versus-host disease, viral pneumonia, and early therapy-related toxicity were the major causes of failure. High-dose chemotherapy and total-body irradiation followed by allogeneic marrow transplantation performed during complete or partial remission can produce long-term remission of acute leukemia.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6245359     DOI: 10.1056/NEJM198005083021901

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  38 in total

Review 1.  Bone marrow transplantation: a review.

Authors:  R E Hardy; E V Ikpeazu
Journal:  J Natl Med Assoc       Date:  1989-05       Impact factor: 1.798

Review 2.  Allogeneic hematopoietic cell transplantation: from experimental biology to clinical care.

Authors:  Razvan Diaconescu; Rainer Storb
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-28       Impact factor: 4.553

3.  Blood and marrow transplantation: a perspective from the University of Minnesota.

Authors:  John H Kersey
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

4.  Allogeneic and autologous bone-marrow transplantation.

Authors:  H J Deeg
Journal:  Can Fam Physician       Date:  1988-11       Impact factor: 3.275

5.  Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.

Authors:  M A Kharfan-Dabaja; M Labopin; A Bazarbachi; R M Hamladji; D Blaise; G Socié; B Lioure; A Bermudez; L Lopez-Corral; R Or; W Arcese; N Fegueux; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-06-30       Impact factor: 5.483

6.  Bone marrow transplantation.

Authors:  E Beutler
Journal:  West J Med       Date:  1989-12

7.  Transplantation of bone marrow with constitutional chromosomal anomalies. Cytogenetic studies and clinical implications.

Authors:  R Becher; H K Mahmoud; U W Schaefer; C G Schmidt
Journal:  Blut       Date:  1986-10

Review 8.  Progress in bone marrow transplantation in man.

Authors:  R P Gale
Journal:  Surv Immunol Res       Date:  1982

9.  Toxicity of ASTA Z 7557 (INN mafosfamide) to normal- and leukemic stem cells: implications for autologous bone marrow transplantation.

Authors:  A Hagenbeek; A C Martens
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

10.  Hematopoietic differentiation of embryoid bodies derived from the human embryonic stem cell line SNUhES3 in co-culture with human bone marrow stromal cells.

Authors:  Seok Jin Kim; Byung Soo Kim; Suck Won Ryu; Ji Hyun Yoo; Jee Hyun Oh; Chang Hee Song; Sun Haeng Kim; Dong Seop Choi; Jae Hong Seo; Chul Won Choi; Sang Won Shin; Yeul Hong Kim; Jun Suk Kim
Journal:  Yonsei Med J       Date:  2005-10-31       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.